| Heading: |
Tofersen |
| Question ID: |
1798241 |
| UIN: |
49021 |
| House: |
Commons |
| Date tabled: |
2025-04-29 |
| Asking Member ID: |
4623 |
| Asking Member display name: |
Tonia Antoniazzi
|
| Asking Member handle: |
ToniaAntoniazzi
|
| Asking Member Twitter reference: |
@ToniaAntoniazzi
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of access to Tofersen through the Early Access Programme for people with SOD1 motor neurone disease. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-05-08 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Companies may put in place Early Access Programmes (EAPs) to allow for early access to new medicines that do not yet have a marketing authorisation. Participation in EAPs is decided at an individual National Health Service trust level, and under these pro... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |